WWIKY Awarded Alberta Innovates AICE Grant
WWiKY is pleased to announce to receive an Alberta Innovates AICE – Validate Program award to develop its ‘next generation’ product for theraostic management of solid hypoxic tumors.
WWIKY selected by Scale U Canada
WWiKY is highly honored to be selected by Scale U Canada as one of the top 50 most scalable companies of Edmonton and 250 most scalable companies of Canada.
WWIKY awarded NRC-IRAP GRant
WWiKY was recently awarded a NRC-IRAP grant to facilitate marketing of its one of the products Hypoxycin-M, which is an ‘antibody-free’ time- and cost-effective product for imaging and quantifying cellular hypoxia. This product will be highly useful in evaluating ‘biopsy-based’ evaluation of therapeutic effectiveness of cancer treatments.
Collaboration with Proholistic Discovery Announced
It is an extreme pleasure to announce that WWiKY Biosciences Inc. is working in collaboration with Proholistic Discovery, Edmonton on an Edmonton Unlimited supported ‘Expert on Demand project to develop an AI-based human PK/PD model for its ‘hypoxia theranostic clinical product’ Hypoxycin-1 – a radiotheranostic product for imaging and treating hypoxic tumors of many cancer types.
Prof. Ravin Narain joins as a collaborator with WWiKY.
Dr. Ravin Narain, a Biomedical Engineer at the Faculty of Engineering, University of Alberta, Edmonton, Canada, is collaborating with WWiKY Biosciences Inc. on the preclinical and translational development of innovative thermoresponsive nanotheranostics for the management of hypoxic tumors.
‘No Objection’ Received from Health Canada
WWiKY BioScienes Inc. has received ‘no objection’ from Health Canada to start a Phase I/II theranostic clinical trial in cancer patients. Dr. Michael Sawyer at the Cross Cancer Institute is leading this trial.
Prof. Yvonne Mowery joins Collaboration with WWiKY
Prof. Yvonne Mowery, a well-known radiation oncologist from Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburgh, USA, is collaborating with WWiKY BioSciences on multi-modal therapy evaluation of our pipeline product.
Prof. Tim Smith joins Collaboration with WWiKY
Prof. Tim Smith, Nuclear Futures Institute, Bangor University, United Kingdom, is collaborating with WWiKY BioSciences on therapy evaluation of our pipeline products.